



NEWS RELEASE

MicroPhage names Mel Schatz to Board of Directors

Longmont, CO, September 30, 2010 – MicroPhage, Inc. announced today that Mel Schatz has been named to the company's board of directors. Mr. Schatz is an experienced industry executive and has held senior leadership positions at Abbott Diagnostics, Medtronic, Bacchus Vascular and is the current President and CEO of at Crux Biomedical.

"This is a very exciting time to be joining MicroPhage. The company is executing a well-targeted product line strategy focused on products that can truly help clinicians treat critically ill patients", said Mr. Schatz.

"Mel is a great addition who brings a breadth of experience at commercial execution and organization scale up as MicroPhage launches its first MRSA products and focuses on commercialization strategy. Mel's expertise in lateral flow devices will help the company drive cost effective sourcing and production of its patented MicroPhage LFI. Mel will be able to provide assistance to the company with financial and strategic deal making as well." said Gary Mesch, Executive Chairman of the Board for MicroPhage.

Mel Schatz has over 30 years in the healthcare arena managing worldwide businesses in the areas of medical devices and diagnostics. His diagnostic experience includes 10 years with Marion Scientific building its microbiology franchise. He subsequently was with Abbott Diagnostics for 15 years where he managed its Cancer Business Unit and also served as Vice President of its Asia Pacific Area and Chairman of its Dainabot joint venture in Japan. Mel is currently serving as President and CEO of Crux Biomedical, a privately funded vascular device firm, headquartered in Menlo Park, California. He holds a BS in Economics from the U. of Maryland and an MBA from Rockhurst College.

"I am very excited with the opportunity to serve on the MicroPhage Board of Directors. The company's patented phage amplification technique has both broad applicability and exquisite performance. The commercial opportunity for a platform that can provide both rapid identification of a pathogen and drug sensitivity, based on my experience, is very large", said Mr. Schatz.

MicroPhage has begun shipping its first product, MRSA/MSSA Blood Culture, into international markets and has recently applied to the U.S. FDA for 510k clearance of this product in the United States.

About MicroPhage

Based in Longmont, Colorado, privately held MicroPhage, Inc. is working to be a global leader in developing rapid, easy-to-use diagnostic products for bacterial identification and antibiotic susceptibility/resistance testing. Using its proprietary Bacteriophage Amplification platform, the Company has developed patented processes that are a platform for rapid, easy-to-use, inexpensive diagnostic and screening tests. The technology platform resembles a home pregnancy test with twin, rapid detectors. The platform does not require any instrumentation and is simple to operate, enabling microbiology testing outside of traditional laboratory settings.

For further information please contact:

Brian MacDonald, VP Marketing & Sales, MicroPhage, Inc., 303-652-5072